How has Corvus Pharmaceuticals's operating lease liabilities changed year-over-year?

Corvus Pharmaceuticals's operating lease liabilities decreased by 432.3% year-over-year, from $31K to -$103K.

What is the long-term trend for Corvus Pharmaceuticals's operating lease liabilities?

Over 2 years (2022 to 2025), Corvus Pharmaceuticals's operating lease liabilities has grown at a -57.9% compound annual growth rate (CAGR), from -$1.05M to -$185K.

Corvus Pharmaceuticals CRVS Operating lease liabilities

Operating lease liabilities at other companies

Iovance Biotherapeutics, Inc.IOVA

——

Vor BiopharmaVOR

——

Protagonist TherapeuticsPTGX

——

Oruka Therapeutics, Inc.ORKA

——

ArriVent BioPharma, Inc.AVBP

——

ImmunomeIMNM

——

Other financials

Income statement

See full

Operating income-$14.9M-49.9%

Net income-$13.7M-190%

EPS (diluted)-$0.15-15.4%

Balance sheet

See full

Cash & equivalents$40.1M+702%

Total debt$834.0K-27.7%

Total equity$240.7M+388%

Total assets$253.2M+326%

Cash flow

See full

Operating cash flow-$10.4M-25.5%

CapEx$91.0K+153%

Free cash flow-$10.5M-26.1%

Valuation

See full

Market cap$1.1B+259%

Enterprise value$1.06B+251%

Returns & leverage

See full

Return on equity-30.5%-12.5pp

Debt / equity0×0.0×

Current ratio19.8×+14.9×

Where this comes from

Reported directly by Corvus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Corvus Pharmaceuticals's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Corvus Pharmaceuticals's operating lease liabilities?: Corvus Pharmaceuticals (CRVS) reported operating lease liabilities of -$103K in Q1 2026.
How has Corvus Pharmaceuticals's operating lease liabilities changed year-over-year?: Corvus Pharmaceuticals's operating lease liabilities decreased by 432.3% year-over-year, from $31K to -$103K.
What is the long-term trend for Corvus Pharmaceuticals's operating lease liabilities?: Over 2 years (2022 to 2025), Corvus Pharmaceuticals's operating lease liabilities has grown at a -57.9% compound annual growth rate (CAGR), from -$1.05M to -$185K.